Taysha Gene Therapies, Inc.
No enriched coverage for $TSHA in the last 7 days.
Taysha Gene Therapies (NASDAQ:TSHA) priced an underwritten public offering of 32.5M shares at $6 each on June 24, plus prepaid warrants for 833,333 shares at $5.999 per warrant. The company expects about $200M gross proceeds and a 30-day option for up to 5M more shares. Bank of America raised its TSHA target to $10 from $9 and reiterated Buy after Part A REVEAL Rett syndrome study updates.
Taysha Gene Therapies said its R&D chief sold about $1.2 million of stock under a 10b5-1 plan, after a 149% share run. The executive still holds 936,410 shares. The company also reaffirmed FDA alignment for TSHA-102’s BLA pathway, citing REVEAL trial dosing completion of 17 patients and early durable results, with $276.6 million cash into 2028.
Nagendran Sukumar (President and Head of R&D) sold 200,000 shares of Taysha Gene Therapies, Inc. (TSHA) at $6.24 ($1.25M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
Recent TSHA coverage spans financial news, corporate actions and insider activity.
In the last 30 days, TSHA insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($1.2M). The most active reporter was Nagendran Sukumar, President and Head of R&D, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The priced equity raise is a near-term dilution overhang, but the size and proceeds can also extend cash runway for TSHA-102 development.
Insider selling is likely routine, but the article ties it to ongoing clinical and regulatory milestones for TSHA-102, which can drive near-term sentiment and risk pricing.
This is an insider open-market sale under a pre-arranged 10b5-1 plan, which typically has limited signaling value but can still affect near-term sentiment.
The filing discloses a new equity/warrant issuance that can pressure near-term price via dilution and overhang, while funding operations.
The upcoming proxy vote at Taysha Gene Therapies (TSHA) on June 1, 2026, involves key governance decisions, including executive compensation and board appointments. The disclosed executive pay for 2025, notably the CEO's over $4 million compensation, may influence investor sentiment and stock performance.
alphai scores every news story that mentions TSHA with an AI model for sentiment and relevance, and aggregates insider trades from Taysha Gene Therapies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Taysha Gene Therapies (NASDAQ:TSHA) priced an underwritten public offering of 32.5M shares at $6 each on June 24, plus prepaid warrants for 833,333 shares at $5.999 per warrant. The company expects about $200M gross proceeds and a 30-day option for up to 5M more shares. Bank of America raised its TSHA target to $10 from $9 and reiterated Buy after Part A REVEAL Rett syndrome study updates.
4 min readTaysha Gene Therapies said its R&D chief sold about $1.2 million of stock under a 10b5-1 plan, after a 149% share run. The executive still holds 936,410 shares. The company also reaffirmed FDA alignment for TSHA-102’s BLA pathway, citing REVEAL trial dosing completion of 17 patients and early durable results, with $276.6 million cash into 2028.
4 min readNagendran Sukumar (President and Head of R&D) sold 200,000 shares of Taysha Gene Therapies, Inc. (TSHA) at $6.24 ($1.25M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
1 min readTaysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d121397dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Taysha Gene Therapies, Inc. Common Stock Pre-Funded Warrants Underwriting Agreement June 24, 2026 Jefferies LLC Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Schedule I hereto c/o Jefferies LLC
4 min readTaysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced the agenda for its annual stockholder meeting on June 1, 2026, which includes voting on the election of two Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Stockholders will also decide the preferred frequency for future "say-on-pay" votes. The proxy statement details executive compensation for 2025, with CEO Sean Nolan receiving over $4 million, and lists major beneficial owners.
3 min readA Form 144 filing indicates that Sukumar Nagendran, an insider at Taysha Gene Therapies (NASDAQ: TSHA), proposes to sell 200,000 shares of the company's stock. The proposed sale, dated January 12, 2026, is valued at $942,740 and includes previously granted RSUs and stock options. This is a routine disclosure required for insider sales, providing transparency about the planned transaction.
2 min readTaysha Gene Therapies is advancing its pivotal clinical trial for TSHA-102, a gene therapy for Rett syndrome, with patient enrollment progressing. The company has outlined a plan for a Biologics License Application (BLA) submission in 2026 to the FDA, following discussions and encouraging interim data. This strategy aims to bring the potential treatment to patients sooner by leveraging existing data.
3 min readTaysha Gene Therapies (Nasdaq: TSHA) announced it will release its full-year 2025 financial results and host a conference call and webcast on Thursday, March 19, 2026, at 8:30 AM Eastern Time. The clinical-stage biotechnology company focuses on AAV-based gene therapies for severe monogenic central nervous system diseases, with its lead program TSHA-102 targeting Rett syndrome. An archived replay of the webcast will be available on the company's website.
2 min readTaysha Gene Therapies Inc (TSHA) is trading near its 52-week high, driven by advancements in its Rett syndrome program and a "Buy" upgrade from Goldman Sachs with an $11 price target. The company received FDA Breakthrough Therapy Designation for TSHA-102 and finalized its REVEAL trial protocol, including a six-month interim analysis that could support a future Biologics License Application. Taysha also regained full rights to TSHA-102, enhancing strategic flexibility and contributing to regulatory clarity and market optimism.
4 min readTaysha Gene Therapies, Inc. ( NASDAQ:TSHA ) stock is trading lower on Friday, with a session volume of 4.695 million, as per data from Benzinga Pro. On Thursday, during after-hours trading, the company said it regained full rights to its lead TSHA-102 program in clinical evaluation for Rett ...
2 min read
